| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Esperion Therapeutics, Inc.
$3.18
0 (0%)
Last traded Jul 10, 2026. This price is not current.
C 51Pipeline Score Fair Value Pharma · Commercial
Market Cap
805.76 M
EPS
-0.06
P/E Ratio
-
Value Trade
78.71 M
0.32 %
Week
62.18 %
1 Month
-10.57 %
3 Month
6.1 %
6 Month
-84.94 %
5 Year
-81.59 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
59.09 M
52 Week Range
0.79 - 4.18
% held by Insiders
-
% held by Institutions
71.64 %
Enterprise Value
1.19 B
Total Shares
239.09 M
Short %
7.43 %
Float Shares
234.07 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Esperion Therapeutics, Inc.
887Total events
15Upcoming
273Tier-1 (high impact)
2015 – 2036Coverage
Upcoming catalysts 2
TBD
T2Other Regulator Milestone
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
◆AcquiredCorporate
Subscribe to view catalyst details
TBD
◆Oral Presentationbempedoic acidApprovedPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-05-24 | bempedoic acid | Phase 2 data readout | Phase 2 | — | – | – | – |
2026-05-24 | bempedoic acid | Phase 2 data readout | Phase 2 | — | – | – | – |
2026-05-24 | bempedoic acid | Phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
C51
Pipeline Score $1.7B
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored2.2x
rNPV / MCap Top 82%
Micro Cap (rank 169 of 933)
Percentile RankEsperion Therapeutics, Inc. carries a moderate pipeline score (51/100), with $4.3B risk-adjusted pipeline value, led by Bempedoic acid+ Ezetimibe in Diabetes (Phase 2), across $192B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bempedoic acid Small molecule | Hypercholesterolemia | Phase 3 | NCT05694260 | 53% | $2.5B | COMPLETED | 3,008 | - | - | Jun 4, 2025 | - | MEDIUM Aug 17, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
bempedoic acid | heterozygous familial hypercholesterolemia | Phase 2 | 2026-05-26 | 30% or greater reduction in LDL-C; 42% of patients in the bempedoic acid arm demonstrated a ≥30% LDL‐C reduction at 3 months; LDL-C reduction in pediatric patients (range 6-25%) Read More | Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 Read More | |
bempedoic acid | heterozygous familial hypercholesterolemia | Phase 2 | 2026-05-26 | 30% or greater reduction in LDL-C; 42% of patients in the bempedoic acid arm demonstrated a ≥30% LDL‐C reduction at 3 months; LDL-C reduction in pediatric patients (range 6-25%) Read More | Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 Read More | |
bempedoic acid | heterozygous familial hypercholesterolemia | Phase 2 | 2026-05-26 | 30% or greater reduction in LDL-C; 42% of patients in the bempedoic acid arm demonstrated a ≥30% LDL‐C reduction at 3 months; LDL-C reduction in pediatric patients (range 6-25%) Read More | Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ESPR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ESPR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How ESPR ranks across every disease it competes inCompetitive Position is a premium feature
See how ESPR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial